Jeffrey T Schouten

Summary

Affiliation: University of Washington
Country: USA

Publications

  1. ncbi A prospective study of hearing changes after beginning zidovudine or didanosine in HIV-1 treatment-naïve people
    Jeffrey T Schouten
    Department of Surgery, University of Washington, Seattle, USA
    BMC Infect Dis 6:28. 2006
  2. ncbi Substitution of nevirapine because of efavirenz toxicity in AIDS clinical trials group A5095
    Jeffrey T Schouten
    University of Washington, Seattle, USA
    Clin Infect Dis 50:787-91. 2010
  3. ncbi Evidence for limited genetic compartmentalization of HIV-1 between lung and blood
    Laura Heath
    Department of Microbiology, University of Washington, Seattle, WA, USA
    PLoS ONE 4:e6949. 2009
  4. ncbi Effects of metformin and rosiglitazone in HIV-infected patients with hyperinsulinemia and elevated waist/hip ratio
    Kathleen Mulligan
    University of California at San Francisco, San Francisco General Hospital, San Francisco, California, USA
    AIDS 21:47-57. 2007
  5. ncbi Efavirenz-based regimens in treatment-naive patients with a range of pretreatment HIV-1 RNA levels and CD4 cell counts
    Heather J Ribaudo
    Center for Biostatistics in AIDS Research, Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts 02115, USA
    J Infect Dis 197:1006-10. 2008
  6. ncbi Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy
    Judith S Currier
    Circulation 118:e29-35. 2008

Detail Information

Publications6

  1. ncbi A prospective study of hearing changes after beginning zidovudine or didanosine in HIV-1 treatment-naïve people
    Jeffrey T Schouten
    Department of Surgery, University of Washington, Seattle, USA
    BMC Infect Dis 6:28. 2006
    ..The goal of this study was to conduct a prospective assessment of the contribution of zidovudine (ZDV) and didanosine (ddI) to hearing loss...
  2. ncbi Substitution of nevirapine because of efavirenz toxicity in AIDS clinical trials group A5095
    Jeffrey T Schouten
    University of Washington, Seattle, USA
    Clin Infect Dis 50:787-91. 2010
    ..Substitution of nevirapine because of efavirenz toxicity was generally safe and efficacious. Clinical trials registration. NCT00013520 ...
  3. ncbi Evidence for limited genetic compartmentalization of HIV-1 between lung and blood
    Laura Heath
    Department of Microbiology, University of Washington, Seattle, WA, USA
    PLoS ONE 4:e6949. 2009
    ..The unique environment of the lung, rich in alveolar macrophages and with specialized local immune responses, may contribute to differential evolution or selection of HIV-1...
  4. ncbi Effects of metformin and rosiglitazone in HIV-infected patients with hyperinsulinemia and elevated waist/hip ratio
    Kathleen Mulligan
    University of California at San Francisco, San Francisco General Hospital, San Francisco, California, USA
    AIDS 21:47-57. 2007
    ..To evaluate the effects of metformin and rosiglitazone, alone or in combination, on fat distribution, insulin sensitivity, and lipids in HIV-infected patients with insulin resistance and changes in fat distribution...
  5. ncbi Efavirenz-based regimens in treatment-naive patients with a range of pretreatment HIV-1 RNA levels and CD4 cell counts
    Heather J Ribaudo
    Center for Biostatistics in AIDS Research, Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts 02115, USA
    J Infect Dis 197:1006-10. 2008
    ..There were no significant differences among subgroups with respect to treatment responses. These results demonstrate the potency of efavirenz-containing regimens across a spectrum of pretreatment VLs and CD4 counts...
  6. ncbi Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy
    Judith S Currier
    Circulation 118:e29-35. 2008